390 related articles for article (PubMed ID: 12614985)
1. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
Serrano Mdel C; Valverde-Conde A; Chávez M M; Bernal S; Claro RM; Pemán J; Ramirez M; Martín-Mazuelos E
Diagn Microbiol Infect Dis; 2003 Feb; 45(2):131-5. PubMed ID: 12614985
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.
Pfaller MA; Marco F; Messer SA; Jones RN
Diagn Microbiol Infect Dis; 1998 Apr; 30(4):251-5. PubMed ID: 9582584
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.
Pfaller MA; Duncanson F; Messer SA; Moet GJ; Jones RN; Castanheira M
Antimicrob Agents Chemother; 2011 Nov; 55(11):5155-8. PubMed ID: 21844312
[TBL] [Abstract][Full Text] [Related]
5. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
Philip A; Odabasi Z; Rodriguez J; Paetznick VL; Chen E; Rex JH; Ostrosky-Zeichner L
Antimicrob Agents Chemother; 2005 Aug; 49(8):3572-4. PubMed ID: 16048988
[TBL] [Abstract][Full Text] [Related]
6. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.
Diekema DJ; Messer SA; Hollis RJ; Jones RN; Pfaller MA
J Clin Microbiol; 2003 Aug; 41(8):3623-6. PubMed ID: 12904365
[TBL] [Abstract][Full Text] [Related]
7. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients.
Chávez M; Bernal S; Valverde A; Gutierrez MJ; Quindós G; Mazuelos EM
J Antimicrob Chemother; 1999 Nov; 44(5):697-700. PubMed ID: 10552989
[TBL] [Abstract][Full Text] [Related]
8. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
[TBL] [Abstract][Full Text] [Related]
9. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species.
O'Shaughnessy EM; Meletiadis J; Stergiopoulou T; Demchok JP; Walsh TJ
J Antimicrob Chemother; 2006 Dec; 58(6):1168-76. PubMed ID: 17071635
[TBL] [Abstract][Full Text] [Related]
10. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
11. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods.
Castanheira M; Duncanson FP; Diekema DJ; Guarro J; Jones RN; Pfaller MA
Antimicrob Agents Chemother; 2012 Jan; 56(1):352-7. PubMed ID: 22083469
[TBL] [Abstract][Full Text] [Related]
12. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
13. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
Cuenca-Estrella M; Gomez-Lopez A; Garcia-Effron G; Alcazar-Fuoli L; Mellado E; Buitrago MJ; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2005 Mar; 49(3):1232-5. PubMed ID: 15728937
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis.
Lalitha P; Shapiro BL; Srinivasan M; Prajna NV; Acharya NR; Fothergill AW; Ruiz J; Chidambaram JD; Maxey KJ; Hong KC; McLeod SD; Lietman TM
Arch Ophthalmol; 2007 Jun; 125(6):789-93. PubMed ID: 17562990
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Activities of Five Antifungal Drugs Against Opportunistic Agents of Aspergillus Nigri Complex.
Badali H; Fakhim H; Zarei F; Nabili M; Vaezi A; Poorzad N; Dolatabadi S; Mirhendi H
Mycopathologia; 2016 Apr; 181(3-4):235-40. PubMed ID: 26615417
[TBL] [Abstract][Full Text] [Related]
16. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.
Perea S; Gonzalez G; Fothergill AW; Kirkpatrick WR; Rinaldi MG; Patterson TF
Antimicrob Agents Chemother; 2002 Sep; 46(9):3039-41. PubMed ID: 12183266
[TBL] [Abstract][Full Text] [Related]
17. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
Marco F; Pfaller MA; Messer SA; Jones RN
Diagn Microbiol Infect Dis; 1998 Sep; 32(1):33-7. PubMed ID: 9791755
[TBL] [Abstract][Full Text] [Related]
18. In vitro antifungal susceptibility of clinical species belonging to Aspergillus genus and Rhizopus oryzae.
Kachuei R; Khodavaisy S; Rezaie S; Sharifynia S
J Mycol Med; 2016 Mar; 26(1):17-21. PubMed ID: 26852191
[TBL] [Abstract][Full Text] [Related]
19. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
Espinel-Ingroff A
J Clin Microbiol; 1998 Oct; 36(10):2950-6. PubMed ID: 9738049
[TBL] [Abstract][Full Text] [Related]
20. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.
Meletiadis J; Stergiopoulou T; O'Shaughnessy EM; Peter J; Walsh TJ
Antimicrob Agents Chemother; 2007 Jun; 51(6):2053-64. PubMed ID: 17387150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]